Short-course quinazoline drug treatments are effective in the Litomosoides sigmodontis and Brugia pahangi jird models.
Ontology highlight
ABSTRACT: The quinazolines CBR417 and CBR490 were previously shown to be potent anti-wolbachials that deplete Wolbachia endosymbionts of filarial nematodes and present promising pre-clinical candidates for human filarial diseases such as onchocerciasis. In the present study we tested both candidates in two models of chronic filarial infection, namely the Litomosoides sigmodontis and Brugia pahangi jird model and assessed their long-term effect on Wolbachia depletion, microfilariae counts and filarial embryogenesis 16-18 weeks after treatment initiation (wpt). Once per day (QD) oral treatment with CBR417 (50 mg/kg) for 4 days or twice per day (BID) with CBR490 (25 mg/kg) for 7 days during patent L. sigmodontis infection reduced the Wolbachia load by >99% and completely cleared peripheral microfilarem
SUBMITTER: Hubner MP
PROVIDER: S-EPMC6931063 | biostudies-literature | 2020 Apr
REPOSITORIES: biostudies-literature
ACCESS DATA